Express Pharma
JULY 2, 2025
Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123 in Japan (generic name: thrombomodulin alfa; marketed as Recomodulin Injection in Japan) for the prevention of chemotherapy-induced peripheral neuropathy (CIPN) related symptoms.
Pharmacy Times
JUNE 17, 2025
Eligible patients include adults (≥ 18 years) diagnosed with CML receiving imatinib as first-line therapy for more than 1 month between 2008 and 2023. Materials and Methods This retrospective observational study utilized the Carolina Data Warehouse for Health electronic health record (EHR) database.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
RX Note
MARCH 31, 2025
Patients on chemotherapy, oral corticosteroids or drugs for HIV May be susceptible to more severe infection. Cold sores located in the mouth or close to the eye Outside scope of community pharmacy. Lesions that spread away from the lips and onto the face Impetigo more likely.
European Pharmaceutical Review
APRIL 3, 2023
In the Phase I New Approaches to Neuroblastoma Therapy (NANT) trial, researchers found that lorlatinib given alone or in combination with chemotherapy was safe and tolerable in patients with relapsed/refractory anaplastic lymphoma kinase (ALK)-driven neuroblastoma. In 2008, the ALK gene was found to hold a key role in the disease.
European Pharmaceutical Review
DECEMBER 12, 2024
This authorisation of the antibody drug conjugate Elahere provides a much needed clinically meaningful option for women living with this type of ovarian cancer, whose disease returns because they develop resistance to platinum-based chemotherapy regimens. 2008; 28(6A):35673572. Int J Gynecol Cancer. 2022; 32(6). Anticancer Res.
pharmaphorum
JUNE 8, 2021
Chemotherapy still accounted for 72.6% Chemotherapy still plays a significant role in oncology treatment, accounting for 72.6% While all of the top ten best-selling oncology drugs in the US in 2019 were innovative therapies, four out of the top ten best-selling oncology drugs in China were for conventional chemotherapy. “In
pharmaphorum
SEPTEMBER 21, 2022
billion buyout of Millennium Pharma way back in 2008 – but those were dashed in 2015 when the drug failed to move the needle in a trial involving patients with peripheral T-cell lymphoma (PTCL). Takeda is also in line for just over $287 million in potential milestone payments, plus royalties on net sales if it reaches the market.
Expert insights. Personalized for you.
59 
Let's personalize your content